AstraZenica: new EU approval for Ultomiris
(CercleFinance.com) - AstraZeneca announced on Wednesday that the European Union has approved the use of Ultomiris in the treatment of neuromyelitis optica spectrum disorder, a rare autoimmune disease.
The Commission's green light, which follows a favourable opinion from the CHMP, is for adult patients with this demyelinating disease that results in acute optic neuritis.
Ultomiris is a terminal complement inhibitor that specifically binds to and has a high affinity for the complement protein C5, thereby inhibiting its cleavage into the pro-inflammatory anaphylatoxin.
The drug was already indicated in Europe for paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome, two other rare diseases.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The Commission's green light, which follows a favourable opinion from the CHMP, is for adult patients with this demyelinating disease that results in acute optic neuritis.
Ultomiris is a terminal complement inhibitor that specifically binds to and has a high affinity for the complement protein C5, thereby inhibiting its cleavage into the pro-inflammatory anaphylatoxin.
The drug was already indicated in Europe for paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome, two other rare diseases.
Copyright (c) 2023 CercleFinance.com. All rights reserved.